| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Bellevue Chest and Mycobacteriology Services (Drs. Donnabella, Salazar-Schicchi, and Rom), Division of Pulmonary and Critical Care Medicine, and Departments of Medicine, Environmental Medicine, and Pathology (Mr. Bonk and Dr. Hanna), New York University School of Medicine, New York, NY.
Correspondence to: Vincent Donnabella, MD, Bellevue Chest and Mycobacteriology Services, Division of Pulmonary and Critical Care Medicine, New York University School of Medicine, 550 1st Ave, New York, NY 10016; e-mail: donnav01{at}popmail.med.nyu.edu
Study objectives: To investigate the dramatic rise in number of Mycobacterium xenopi isolates identified in our mycobacteriology laboratory, and to determine if this increase was due to emerging clinical pathology or to changes in culture technique.
Design: Retrospective chart and laboratory review.
Setting: University-affiliated tertiary-care city hospital.
Patients: Eighty-one patients with a single culture positive for M xenopi from 1975 to 1994 (period 1), and 47 patients with two or more cultures positive from 1994 to 1998 (period 2).
Interventions: The Bellevue mycobacteriology laboratory changed the culture medium from solid Lowenstein-Jensen medium (used from 1975 to 1990) to the Septi-Check AFB System (Becton-Dickinson; Glencoe, MD; used from 1991 to 1994), to the Mycobacteria Growth Indication Tube (MGIT; Becton-Dickinson; used from 1995 to 1998).
Measurements and results: We recovered 29 M xenopi isolates from 1975 to 1990, 12 isolates from 1991 to 1994, and 381 isolates from 1995 to 1998. We subsequently identified and reviewed the medical records of all 81 patients who were culture positive for M xenopi from 1975 to 1994 (period 1), and 46 patients who had two or more isolates culture positive for M xenopi from 1995 to 1998 (period 2). For period 1, 75% of the subjects were male, 80% were minority, and at least 43% were HIV positive. Only one patient had clinical M xenopi lung disease during this period. For period 2, 79% of the subjects were male, 83% were minority, and at least 58% were HIV positive; two additional patients were identified who had clinical M xenopi lung disease.
Conclusions: The dramatic increase in M xenopi isolates noted in our hospital was due to a more sensitive laboratory isolation technique, rather than a true increase in clinical disease. Other hospitals utilizing MGIT systems for mycobacterial recovery should interpret positive M xenopi cultures with caution.
Key Words: clinical review • laboratory methods • Mycobacterium xenopi • nontuberculous mycobacteria
This article has been cited by other articles:
|
|
 |
|
  T. Bossert, H. B. Bittner, M. Richter, A. Rahmel, M. Barten, J. F. Gummert, and F. W. Mohr Successful Management of Two Heart Transplant Recipients With Mycobacterial Pulmonary Infections Ann. Thorac. Surg., August 1, 2005; 80(2): 719 - 721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Meybeck, C. Fortin, S. Abgrall, H. Adle-Biassette, G. Hayem, R. Ruimy, and P. Yeni Spondylitis Due to Mycobacterium xenopi in a Human Immunodeficiency Virus Type 1-Infected Patient: Case Report and Review of the Literature J. Clin. Microbiol., March 1, 2005; 43(3): 1465 - 1466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Salazar-Schicchi, S A Nachman, C Bachmeyer, S Stelianides, and L Blum Mycobacterium xenopi Thorax, July 1, 2002; 57(7): 658 - 658. [Full Text] [PDF]
|
|
|
|
|
|
L. Lang-Lazdunski, C. Offredo, F. Le Pimpec-Barthes, C. Danel, A. Dujon, and M. Riquet Pulmonary resection for Mycobacterium xenopi pulmonary infection Ann. Thorac. Surg., December 1, 2001; 72(6): 1877 - 1882. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
